586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
Natalie Izaguirre(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Tal Gilboa(Brigham and Women's Hospital), Amy C Sherman(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Megan Powell(Men's Health Boston), Noah Abasciano(Brigham and Women's Hospital), Peter Baker(Dana-Farber Cancer Institute), Chi‐An Cheng(Brigham and Women's Hospital), Jennifer L. Crombie(Dana-Farber Cancer Institute), David R. Walt(Brigham and Women's Hospital), Bruce Bausk, Nicolas C. Issa(Dana-Farber Cancer Institute), Mikaela M. McDonough(Dana-Farber Cancer Institute), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981